cysteamine

(redirected from Mercaptamine)
Also found in: Dictionary.

cysteamine

 [sis-te´ah-mēn″]
a sulfhydryl amine that is part of coenzyme A; it reduces intracellular cystine levels and is used in treatment of nephropathic cystinosis; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

cys·te·a·mine

(sis-tā'a-mēn),
2-Aminoethanethiol; a sulfhydryl compound used experimentally to produce ulcers in rats and as a radioprotective agent; antidote to acetaminophen.
Farlex Partner Medical Dictionary © Farlex 2012

cysteamine

A stable aminothiol and metabolite of the amino acid cysteine.

Physiologic role
Cysteamine forms coenzyme A by combining with pantothenate and adenosine triphosphate.

Potential therapeutic role
Cysteamine has been in clinical trials for managing Batten disease, cystinosis, non-alcoholic steatohepatitis and Huntington's disease.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

cysteamine

Mercaptamine, a drug used to treat NEPHROPATHIC CYSTINOSIS and prescribable only by urological specialists. A brand name is Cystagon.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
* cysteamine (BAN) and its rINN alternative mercaptamine. Mercaptamine is very similar to mercaptopurine.
The company's PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate) has been studied as an orphan medicinal product for the treatment of proven nephropathic cystinosis EC in the European Union (EU).
Biopharmaceutical company Raptor Pharmaceutical Corp (Nasdaq:RPTP) announced on Thursday the approval by the European Commission (EC) of PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), as an orphan medicinal product for the treatment of proven nephropathic cystinosis for marketing in the European Union (EU).